Success Metrics

Active Trials
4(80%)

Phase Distribution

Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

not_yet_recruiting120%
recruiting480%

Recent Activity

4 active trials
Showing 5 of 5
recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798
recruiting

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

NCT03334708
not_yet_recruitingnot_applicable

Targeting MYC in High-Risk Medulloblastoma

NCT07694622
recruiting

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

NCT06606028
recruiting

Establishment of a Tumor Bank for Tissue Samples

NCT01789229

Clinical Trials (5)

Showing 5 of 5 trials
NCT04165798

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Recruiting
NCT03334708

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Recruiting
NCT07694622Not Applicable

Targeting MYC in High-Risk Medulloblastoma

Not Yet Recruiting
NCT06606028

Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

Recruiting
NCT01789229

Establishment of a Tumor Bank for Tissue Samples

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5